Enzon Pharmaceuticals Files 2024 Annual Report
Ticker: ENZN · Form: 10-K · Filed: Feb 21, 2025 · CIK: 727510
Sentiment: neutral
Topics: 10-K, annual-report, biotech
Related Tickers: ENZN
TL;DR
Enzon Pharma's 2024 10-K is in. All systems go for biotech operations.
AI Summary
Enzon Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, incorporated in Delaware and headquartered in Cranford, NJ, operates in the biological products sector. Key financial data and disclosures related to its preferred stock and research activities are included in the filing.
Why It Matters
This filing provides a comprehensive overview of Enzon Pharmaceuticals' financial health and operational status for the past fiscal year, which is crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The provided text is a standard 10-K filing header and does not contain specific financial performance details or forward-looking statements that would indicate high risk.
Key Numbers
- 74,214,603 — Total Assets (Reported for the fiscal year ending 12-31-2024.)
- 40,000 — Common Stock Shares (Reported for the fiscal year ending 12-31-2024.)
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-02-21 (date) — Filing Date
- Cranford, NJ (location) — Business Address
- 732-980-4500 (phone_number) — Business Phone
- Series C Preferred Stock (security) — Preferred Stock Type
FAQ
What is Enzon Pharmaceuticals, Inc.'s primary business sector?
Enzon Pharmaceuticals, Inc. operates in the Biological Products sector, specifically SIC code 2836.
When was the 10-K filing for Enzon Pharmaceuticals, Inc. submitted?
The 10-K filing was submitted on February 21, 2025.
What is the fiscal year end for Enzon Pharmaceuticals, Inc. as reported in this filing?
The fiscal year end is December 31, 2024.
What is the company's business address?
The business address is 20 Commerce Drive, Suite 135, Cranford, NJ 07016.
What type of preferred stock is mentioned in relation to Enzon Pharmaceuticals, Inc.?
Series C Preferred Stock is mentioned in relation to Enzon Pharmaceuticals, Inc.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 21, 2025 regarding ENZON PHARMACEUTICALS, INC. (ENZN).